Treatment options for hypertension in high-risk patients

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Patients are considered to be at high risk of cardiovascular events if they have diabetes, chronic kidney disease, stroke, established coronary artery disease, or a coronary artery disease equivalent. Blood pressure-lowering therapy has been shown to reduce cardiovascular events in these patients significantly. Identification of high-risk patients by global risk evaluation is recommended for every hypertensive patient. Treatment of hypertension in high-risk patients with an angiotensin-converting enzyme inhibitor or an angiotensin receptor antagonist, with or without addition of a dihydropyridine calcium channel antagonist, is a reasonable approach based on current clinical trials.

Original languageEnglish
Pages (from-to)137-141
Number of pages5
JournalVascular Health and Risk Management
Volume7
Issue number1
DOIs
Publication statusPublished - 2011 Jan 1

Fingerprint

Hypertension
Coronary Artery Disease
Therapeutics
Angiotensin Receptor Antagonists
Calcium Channel Blockers
Chronic Renal Insufficiency
Angiotensin-Converting Enzyme Inhibitors
Stroke
Clinical Trials
Blood Pressure

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)
  • Public Health, Environmental and Occupational Health
  • Hematology
  • Endocrinology, Diabetes and Metabolism

Cite this

@article{c7de3ab68e884e2fadf6bd0dc4685d37,
title = "Treatment options for hypertension in high-risk patients",
abstract = "Patients are considered to be at high risk of cardiovascular events if they have diabetes, chronic kidney disease, stroke, established coronary artery disease, or a coronary artery disease equivalent. Blood pressure-lowering therapy has been shown to reduce cardiovascular events in these patients significantly. Identification of high-risk patients by global risk evaluation is recommended for every hypertensive patient. Treatment of hypertension in high-risk patients with an angiotensin-converting enzyme inhibitor or an angiotensin receptor antagonist, with or without addition of a dihydropyridine calcium channel antagonist, is a reasonable approach based on current clinical trials.",
author = "Wei-Chuan Tsai",
year = "2011",
month = "1",
day = "1",
doi = "10.2147/VHRM.S11235",
language = "English",
volume = "7",
pages = "137--141",
journal = "Vascular Health and Risk Management",
issn = "1176-6344",
publisher = "Dove Medical Press Ltd.",
number = "1",

}

Treatment options for hypertension in high-risk patients. / Tsai, Wei-Chuan.

In: Vascular Health and Risk Management, Vol. 7, No. 1, 01.01.2011, p. 137-141.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Treatment options for hypertension in high-risk patients

AU - Tsai, Wei-Chuan

PY - 2011/1/1

Y1 - 2011/1/1

N2 - Patients are considered to be at high risk of cardiovascular events if they have diabetes, chronic kidney disease, stroke, established coronary artery disease, or a coronary artery disease equivalent. Blood pressure-lowering therapy has been shown to reduce cardiovascular events in these patients significantly. Identification of high-risk patients by global risk evaluation is recommended for every hypertensive patient. Treatment of hypertension in high-risk patients with an angiotensin-converting enzyme inhibitor or an angiotensin receptor antagonist, with or without addition of a dihydropyridine calcium channel antagonist, is a reasonable approach based on current clinical trials.

AB - Patients are considered to be at high risk of cardiovascular events if they have diabetes, chronic kidney disease, stroke, established coronary artery disease, or a coronary artery disease equivalent. Blood pressure-lowering therapy has been shown to reduce cardiovascular events in these patients significantly. Identification of high-risk patients by global risk evaluation is recommended for every hypertensive patient. Treatment of hypertension in high-risk patients with an angiotensin-converting enzyme inhibitor or an angiotensin receptor antagonist, with or without addition of a dihydropyridine calcium channel antagonist, is a reasonable approach based on current clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=79960942479&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960942479&partnerID=8YFLogxK

U2 - 10.2147/VHRM.S11235

DO - 10.2147/VHRM.S11235

M3 - Review article

VL - 7

SP - 137

EP - 141

JO - Vascular Health and Risk Management

JF - Vascular Health and Risk Management

SN - 1176-6344

IS - 1

ER -